### ASX/TSX Announcement



23 November 2018

#### Section 708A Cleansing Statement and Appendix 3B

This notice is given by Clean TeQ Holdings Limited (**Clean TeQ** or **Company**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

#### Clean TeQ hereby confirms that:

- a) it has issued 78,192 fully paid ordinary shares (Shares) for nil consideration in accordance with the terms and conditions of the Clean TeQ Holdings Limited Short-Term Incentive Plan;
- b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - ii. section 674 of the Corporations Act as it applies to the Company; and
- e) as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

#### For more information, please contact:

Sam Riggall, CEO or Ben Stockdale, CFO

+61 3 9797 6700

**About Clean TeQ Holdings Limited (ASX/TSX: CLQ)** – Based in Melbourne, Australia, Clean TeQ is a global leader in metals recovery and industrial water treatment through the application of its proprietary Clean-iX® continuous ion exchange technology. For more information about Clean TeQ please visit the Company's website <a href="www.cleanteq.com">www.cleanteq.com</a>.

**About the Clean TeQ Sunrise Project** – Clean TeQ is the 100% owner of the Clean TeQ Sunrise Project, located in New South Wales. Clean TeQ Sunrise is one of the largest cobalt deposits outside of Africa, and one of the largest and highest-grade accumulations of scandium ever discovered.

**About Clean TeQ Water** – Through its wholly owned subsidiary Clean TeQ Water, Clean TeQ is also providing innovative wastewater treatment solutions for removing hardness, desalination, nutrient removal, zero liquid discharge. The sectors of focus include municipal wastewater, surface water, industrial waste water and mining waste water. For more information about Clean TeQ Water please visit <a href="https://www.cleanteqwater.com">www.cleanteqwater.com</a>.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Clean TeQ Holdings Limited

ABN

34 127 457 916

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- (a) Unquoted performance rights
- (b) Unquoted performance rights
- (c) Fully paid ordinary shares
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- (a) 100,757
- (b) 142,341
- (c) 78,192
- Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- (a) Convertible into fully paid ordinary shares on 1:1 basis subject to the terms of the Company's Employee Incentive Plan and meeting service and performance criteria. Vest date 1 January 2021
- (b) Convertible into fully paid ordinary shares on 1:1 basis subject to the terms of the Company's Employee Incentive Plan and meeting service and performance criteria. Vest date 1 July 2021
- (c) Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

4	Do the +securities rank equally in all
	respects from the date of allotment with an
	existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- (a) No. However fully paid ordinary shares issued pursuant to conversion of performance rights will rank in all respects pari passu with existing shares at the date of issue.
- (b) No. However fully paid ordinary shares issued pursuant to conversion of unlisted options will rank in all respects pari passu with existing shares at the date of issue.
- (c) Yes

5	Locus	nring	or consid	laration
.)	18800	Direct	or consi	ieration

- (a) Nil
- (b) Nil
- (c) Nil
- Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets
- (a) Issue of performance rights to the Managing Director in accordance with Resolution 5 as approved by shareholders at the Company's 2018 Annual General
- (b) Issue of performance rights to the Managing Director in accordance with Resolution 6 as approved by shareholders at the Company's 2018 Annual General Meeting.
- (c) Issue of fully paid ordinary shares to the Managing Director in accordance with Resolution 7 as approved by shareholders at the Company's 2018 Annual General Meeting.
- Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section No

The date the security holder resolution 6b under rule 7.1A was passed

N/A

6c Number of +securities issued without security holder approval under rule 7.1

Nil

6d Number of +securities issued with security holder approval under rule 7.1A

Nil

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify	(a) 100,757 unquoted p (b) 142,341 unquoted p (c) 78,192 fully paid or	erformance rights
	date of meeting)	Annual General Meeting	g – 22 November 2018
6f	Number of securities issued under an exception in rule 7.2	Nil	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
7	Dates of entering *securities into uncertificated holdings or despatch of certificate	23 November 2018	
		NY 1	+01
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	Number 746,244,940	+Class Ordinary fully paid shares
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the securities in	13,000,000	Options over ordinary shares
	section 2 if applicable)	5,594,965	Performance Rights
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part	2 - Bonus issue or pro rata is:	sue	
11	Is security holder approval N/A required?	A	
12	Is the issue renounceable or non-renounceable?	A	

 $<sup>+\</sup>mbox{ See}$  chapter 19 for defined terms.

#### Appendix 3B New issue announcement

13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements in full through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Despatch date	N/A
	Part 3 - Quotation of secu	
	Type of securities (tick one)	
	(a) Securities described in	Part 1
	=	t the end of the escrowed period, partly paid securities that become fully paid, employee estriction ends, securities issued on expiry or conversion of convertible securities
	Entities that have ticked box 3	4(a)
	Additional securities forming a n Tick to indicate you are providing the t	

 $<sup>+\</sup>mbox{ See}$  chapter 19 for defined terms.

#### Appendix 3B New issue announcement

docum	ents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over
37	A copy of any trust deed for the additional *securities
Entiti	ies that have ticked box 34(b)
38	Number of securities for which +quotation is sought
39	Class of *securities for which quotation is sought
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?
	If the additional securities do not rank equally, please state:  1. the date from which they do  2. the extent to which they participate for the next
	dividend, (in the case of a trust, distribution) or
	interest payment  3. the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
41	Reason for request for quotation
	Example: In the case of restricted securities, end of restriction period
	(if issued upon conversion of another security, clearly identify that other security)

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Number and \*class of all \*securities quoted on ASX (*including* the securities in clause 38)

Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here

Company Secretary

Date: 23 November 2018

Print name:

Melanie Leydin

== == == ==

Appendix 3B Page 8 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	579,950,182	
<ul> <li>Add the following:         <ul> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul> </li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which</li> </ul> </li> </ul>	500,000 – 2 January 2018 2,437,762 – 19 January 2018 600,000 – 25 January 2018 7,004,743 – 12 February 2018 1,500,000 – 9 March 2018 86,858,903 – 15 March 2018 13,366,936 – 21 March 2018 43,575,880 – 23 April 2018 4,836,593 – 24 April 2018 1,758,876 – 1 May 2018 367,885 – 28 June 2018 1,646,416 – 3 July 2018	
this form is annexed  It may be useful to set out issues of securities on different dates as separate line items	500,000 – 6 July 2018 750,000 – 22 November 2018 78,192 – 23 November 2018	
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	-	
"A"	745,132,368	

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]

<sup>+</sup> See chapter 19 for defined terms.

<i>Multiply</i> "A" by 0.15	111,769,855	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<ul> <li>Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	600,000 – 25 January 2018 512,572 – 3 September 2018	
"C"	1,112,572	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1  "A" x 0.15  Note: number must be same as shown in Step 2	3"] to calculate remaining  111,769,855	
Subtract "C"  Note: number must be same as shown in Step 3	1,112,572	
<i>Total</i> ["A" x 0.15] – "C"	110,657,283 [Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"  Note: number must be same as shown in Step 1 of Part 1	N/A	
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	-	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	-	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	-	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	-	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.